Drugs / SGB-3403
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06239714 | Feb 2024 → Feb 2025 | hyperlipidemia | Suzhou Sanegene Bio Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGB-3403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239714 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered SGB-3403” NCT06239714 ↗ |